奥沙利铂联合卡培他滨治疗进展期胃癌的临床疗效评估

目的 评估进展期胃癌病人采用奥沙利铂联合卡培他滨治疗的疗效及安全性.方法 纳入治疗的进展期胃癌病人共63例,其中男性28例,女性35例,分为对照组30例,观察组33例;对照组围手术期采用替吉奥联合奥沙利铂方案治疗,观察组围手术期采用奥沙利铂联合卡培他滨方案治疗;比较两组病人的临床疗效、不良反应与生活质量改善程度.结果 对照组总体有效率36.7%,观察组总体有效率为57.6%,观察组高于对照组;观察组口腔黏膜炎症总发生率15.2%,对照组口腔黏膜炎症总发生率46.7%,观察组显著低于对照组(P<0.05);其余各项不良反应指标观察组与对照组差异无统计学意义.观察组生活质量改善率87.9%,对照组生活质量改善率73.3%,观察组高于对照组.结论 奥沙利铂联合卡培他滨对进展期胃癌的治疗作用值得肯定,治疗过程中不良反应发生率较低,有助于改善病人预后.

Assessment of the clinical effect of oxaliplatin in combination with capecitabine regimen in the treatment of advanced gastric cancer

Objective To assess the efficacy and safety of oxaliplatin combined with capecitabine in treating patients with advanced gastric cancer.Methods Sixty-three patients with advanced gastric cancer were enrolled,of which 28 males and 35 females were included.All the patients were assigned into a control group of 30 cases and an observation group of 33 cases.The control group was perioperatively treated with Gio and oxaliplatin regimen,while the observation group was perioperatively treated with oxaliplatin plus capecitabine regimen.Comparison was made between two groups of patients in clinical efficiency,adverse reaction and improvement in the quality of life.Results The total effective rates of the control group and the observation group were 36.7% and 57.6% respectively.The effective rate of the observation group was higher than the control group(P<0.05).The total incidence rate of oral cavity mucous membrane inflammation in observation group was 15.2%,which was significantly lower than 46.7% in control group (P<0.05).The improvement rate of the life quality in the observation group was 87.9%,which was significantly higher than 73.3% in the control group (P<0.05).Conclusions Oxaliplatin combined with capecitabine is an effective treatment for advanced gastric cancer patients,with lower incidence of adverse reactions,and it can improve the quality of life of the patients.